Targeted therapies for the treatment of patients with advanced, recurrent or relapsed thymic epithelial tumours

Thymic epithelial tumours (TETs) are rare neoplasms of the anterior mediastinum with a reported incidence of 
0.15 per million person-year in the United States (1). They are classified into thymomas and thymic carcinomas on the basis of morphological features, the grade of atypia of epithelial cells and their relative proportion to lymphocytes.